Join the Eczema group to help and get support from people like you.
Eczema News
FDA Approves Anzupgo (delgocitinib) Cream for the Treatment of Chronic Hand Eczema
BALLERUP, Denmark, July 23, 2025 – LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Anzupgo® (delgocitinib) cream (20 m...
Novel Treatments Recommended for Management of Atopic Dermatitis in Adults
FRIDAY, July 25, 2025 – In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was published online July 16 in...
FDA Approves First Cream for Treating Chronic Hand Eczema, Anzupgo
THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic hand eczema (CHE). CHE is common condition ma...
High Dietary Inflammatory Index Tied to Increased Prevalence of Eczema
TUESDAY, July 15, 2025 – A high dietary inflammatory index (DII), which quantifies the inflammatory potential of diet, is associated with increased prevalence of atopic dermatitis (AD), according to...
Prevalence, Incidence of Eczema Increase With Severity of Alopecia Areata
MONDAY, July 14, 2025 – Patients with higher-severity alopecia areata (AA) have a higher prevalence and incidence of comorbid atopic dermatitis (AD), according to a study published online June 26 in...
Early Dog Exposure May Modify Genetic Effect on Atopic Eczema Risk
MONDAY, June 9, 2025 – Early-life dog exposure may modify the genetic effect of the single nucleotide variant rs10214237 on atopic eczema (AE) via IL7R, according to a study published online June 4...
Fido Might Protect Your Baby Against Eczema
THURSDAY, June 5, 2025 — Having a family dog might decrease a baby’s risk of developing eczema later in childhood, a new evidence review says. Specifically, exposure to canines appears to influence a ...
New AI Can Help Track Eczema
FRIDAY, May 23, 2025 – Eczema sufferers could soon find it easier to track their skin condition, via a newly developed AI that can assess severity using uploaded smartphone images. The AI...
AI Three-Item Severity Score Can ID Eczema From Patient-Uploaded Images
FRIDAY, May 23, 2025 – An artificial intelligence (AI) Three-Item Severity (TIS) score can identify eczema-affected areas and severity scores from user-uploaded images, according to a research...
AAP Updates Guidelines for Pediatric Atopic Dermatitis Management
MONDAY, May 19, 2025 – In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for the treatment of children with atopic dermatitis ...
Global Burden of Atopic Dermatitis in Older Adults Is Considerable
WEDNESDAY, May 7, 2025 – The global burden of atopic dermatitis (AD) in older adults is considerable and is expected to continue increasing to 2050, according to a study published online April 1 in...
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
WEDNESDAY, April 23, 2025 – Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in JAMA Ophthalmology. Yung-Yu ...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health professionals, and others interested i...
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
FRIDAY, March 14, 2025 – Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in P...
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
FRIDAY, March 14, 2025 – Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment,...
Further information
Related condition support groups
Related drug support groups
prednisone, methotrexate, clobetasol, Dupixent, fluocinonide, dexamethasone, desonide, halobetasol, dupilumab